Alnylam Pharmaceuticals
ALNY
#618
Rank
HK$251.67 B
Marketcap
HK$1,945
Share price
3.33%
Change (1 day)
72.69%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of April 2025 (TTM): 14.4

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 483. At the end of 2024 the company had a P/S ratio of 13.7.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2024

PS ratio at the end of each year

Year P/S ratio Change
202413.73.91%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
728 4,946.95%๐Ÿ‡บ๐Ÿ‡ธ USA
4.59-68.16%๐Ÿ‡บ๐Ÿ‡ธ USA
3.08-78.61%๐Ÿ‡บ๐Ÿ‡ธ USA
1.57-89.13%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
4.26-70.43%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2.68-81.43%๐Ÿ‡ซ๐Ÿ‡ท France
1.02-92.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel